INS and type 2 diabetes mellitus: Additionally, the rates of treatment-emergent adverse events (AEs) were similar for both insulins, with no differences in the rates of adverse cardiovascular events; among patients with T2DM at high risk for cardiovascular events, Deg was noninferior to Glar-100 with respect to the incidence of major cardiovascular events [31–33].